Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development

Journal of Pharmaceutical Sciences

Volumn 101, Issue 12, 2012, Pages 4367-4382

  Zhao, Liang ^a   Shang, Elizabeth Y ^a   Sahajwalla, Chandrahas G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

ADME; Pharmacodynamics; Pharmacokinetic pharmacodynamic models; Pharmacokinetics; Physiological model

Indexed keywords

EID: 84868201883     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23330     Document Type: Review

References (81)

1. Wang W, Wang EQ, Balthasar JP. 2008. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548-558.
2. Maillet A, Congy-Jolivet N, Le GS, Vecellio L, Hamard S, Courty Y, Courtois A, Gauthier F, Diot P, Thibault G, Lemarie E, Heuze-Vourc'h N. 2008. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm Res 25:1318-1326.
3. O'Driscoll c. 1992. Anatomy and physiology of the lymphatics. In Lymphatic transport of drugs; Charman W, Stella V, Eds. Boca Raton, Florida: CRC Press, pp 1-36.
4. Roskos L, Ren S, Robbie G. 2011. Application of modeling and simulation in the development of protein drugs. In Clinical trial simulations AAPS advances in pharmaceutical sciences series; Kimko H, Peck C, Eds. New York, Dordrecht, Heidelberg, London: Springer Science+Business Media, LLC, pp 361-396.
5. 2011. Epogen (epoetin alpha) solution: US prescribing information. Thousand Oaks, California: Amgen Inc.
6. 2010. Xolair (omalizumab): US prescribing information. South San Francisco, California: Genentech, Inc.
7. Lobo ED, Hansen RJ, Balthasar JP. 2004. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668.
8. Antohe F, Radulescu L, Gafencu A, Ghetie V, Simionescu M. 2001. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol 62:93-105.
9. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, Blumberg RS, Lencer WI. 1999. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104:903-911.
10. McCarthy KM, Yoong Y, Simister NE. 2000. Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: A system to study protein transport across epithelia. J Cell Sci 113(Pt 7):1277-1285.
11. Bill A. 1977. Plasma protein dynamics: Albumin and IgG capillary permeability, extravascular movement and regional blood flow in unanesthetized rabbits. Acta Physiol Scand 101:28-42.
12. Hedger MP, Hettiarachchi S. 1994. Measurement of immunoglobulin G levels in adult rat testicular interstitial fluid and serum. J Androl 15:583-590.
13. Juweid M, Strauss HW, Yaoita H, Rubin RH, Fischman AJ. 1992. Accumulation of immunoglobulin G at focal sites of inflammation. Eur J Nucl Med 19:159-165.
14. Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, Larson SM, Keenan AM. 1987. The pharmacology of monoclonal antibodies. Ann N Y Acad Sci 507:199-210.
15. 2011. Humira (adalimumab) kit: US prescribing information. North Chicargo, Illinois: Abbott Laboratories.
16. 2011. Orencia (abatacept) injection, powder, lyophilized, for solution: US prescribing information. Princeton, New Jersey: Bristol-Myers Squibb Company.
17. Gueorguieva I, Clark SR, McMahon CJ, Scarth S, Rothwell NJ, Tyrrell PJ, Hopkins SJ, Rowland M. 2008. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol 65:317-325.
18. Dirks NL, Meibohm B. 2010. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633-659.
19. Garg A, Balthasar JP. 2007. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687-709.
20. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. 2002. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences. J Immunol 169:5171-5180.
21. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES. 1997. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15:637-640.
22. Ober RJ, Radu CG, Ghetie V, Ward ES. 2001. Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies. Int Immunol 13:1551-1559.
23. Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-Lopez AJ, Witzig TE, White CA. 2003. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 18:165-178.
24. Schellekens H. 2002. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24:1720-1740.
25. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vasquez M, Tsurushita N. 2004. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 279:6213-6216.
26. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. 2006. An engineered human IgG1 antibody with longer serum half-life. J Immunol 176:346-356.
27. US Food and Drug Administration. 2005. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Rockville, Maryland: US FDA.
28. Vaccaro C, Zhou J, Ober RJ, Ward ES. 2005. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23:1283-1288.
29. Murphy K, Travers P, Walport M. 2007. Janeway's immunobiology. 7 ed. New York City, New York: Garland Science.
30. 2010. Rituxan (rituimab): US prescribing information. South San Francisco, California: Genentech, Inc.
31. 2010. Herceptin (trastuzumab) kit: US prescribing information. South San Francisco, California: Genentech, Inc.
32. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. 1998. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9:995-1001.
33. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. 1997. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274.
34. Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Perez-Ruixo JJ, Chow AT. 2010. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J 12:729-740.
35. Levi M, Li J, Frey N. 2008. Characterization of the time-varying clearance of rituximab in non-Hodgkin's lymphoma patients using a population pharmacokinetic analysis [abstract no. 9]. American Conference on Pharmacometrics, March 9-12.
36. de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, Nurmohamed MT, Dijkmans BA, Aarden LA, Wolbink GJ. 2009. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 68:1787-1788.
37. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B. 2006. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54:711-715.
38. 2011. Simponi (golimumab) injection, solution: US prescribing information. Horsham, Pennsylvania: Janssen Biotech, Inc.
39. Bernd Meibohm, Rene Braeckman. 2007. Pharmacokinetics and pharmacodynamics of peptide and protein drugs. In Pharmaceutical biotechnology: Fundamentals and applications; Daan JA, Crommelin, Robert D.Sindelar, Bernd Meibohm, Eds. 3rd ed., New York City, New York: Informa Healthcare, pp 95-124.
40. 2011. BEXXAR (tositumomab) kit: US prescribing information. Research Triangle Park, North Carolina: GlaxoSmithKline LLC.
41. Harding FA, Stickler MM, Razo J, DuBridge RB. 2010. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MAbs 2:256-265.
42. 2011. Remicade (infliximab) injection: US prescribing information. Horsham, Pennsylvania: Janssen Biotech, Inc.
43. 2011. Kineret (anakinra): US prescribing information. Stockholm, Sweden: Swedish Orphan Biovitrum AB.
44. 2011. Pegintron (peginterferon alfa-2b): US prescribing information. Whitehouse Station, New Jersey: Schering Corporation, a subsidiary of MERCK & COMPANY, INC.
45. US Food and Drug Administration. 2010. Guidance for industry: Pharmacokinetics in patients with impaired renal function-Study design, data analysis, and impact on dosing and labeling (draft). Rockville, Maryland: US FDA.
46. Mahmood I. 2009. Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation. J Pharm Sci 98:3850-3861.
47. Mahmood I. 2010. Interspecies scaling for the prediction of drug clearance in children: Application of maximum lifespan potential and an empirical correction factor. Clin Pharmacokinet 49:479-492.
48. US Food and Drug Administration. 2005. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Rockville, Maryland: US FDA.
49. Marshall E. 2006. Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. Science 311:1688-1689.
50. Muller PY, Milton M, Lloyd P, Sims J, Brennan FR. 2009. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol 20:722-729.
51. Yu J, Karcher H, Feire AL, Lowe PJ. 2011. From target selection to the minimum acceptable biological effect level for human study: Use of mechanism-based PK/PD modeling to design safe and efficacious biologics. AAPS J 13:169-178.
52. Mould DR, Green B. 2010. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: Concepts and lessons for drug development. BioDrugs 24:23-39.
53. Gibiansky L, Gibiansky E. 2009. Target-mediated drug disposition model: Approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol 5:803-812.
54. Thygesen P, Macheras P, Van PA. 2009. Physiologically-based PK/PD modelling of therapeutic macromolecules. Pharm Res 26:2543-2550.
55. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. 1986. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res 46:3969-3978.
56. Baxter LT, Zhu H, Mackensen DG, Jain RK. 1994. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54:1517-1528.
57. Rippe B, Haraldsson B. 1987. Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations. Acta Physiol Scand 131:411-428.
58. Ferl GZ, Wu AM, DiStefano JJ, III. 2005. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 33:1640-1652.
59. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. 1995. Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55:4611-4622.
60. Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH. 2008. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 8:401-413.
61. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. 1979. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther 25:358-371.
62. Beck BD, Mattuck RL, Bowers TS, Cohen JT, O'Flaherty E. 2001. The development of a stochastic physiologically-based pharmacokinetic model for lead. Sci Total Environ 274:15-19.
63. Cheng H, Gillespie WR. 1996. Volumes of distribution and mean residence time of drugs with linear tissue distribution and binding and nonlinear protein binding. J Pharmacokinet Biopharm 24:389-402.
64. Kristensen NR, Madsen H, Ingwersen SH. 2005. Using stochastic differential equations for PK/PD model development. J Pharmacokinet Pharmacodyn 32:109-141.
65. Lansky P. 1996. A stochastic model for circulatory transport in pharmacokinetics. Math Biosci 132:141-167.
66. Matis JH, Kiffe TR, Matis TI, Stevenson DE. 2005. Nonlinear stochastic modeling of aphid population growth. Math Biosci 198:148-168.
67. Moriwaki T, Yasui H, Yamamoto A. 2003. A recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference. J Pharmacokinet Pharmacodyn 30:119-144.
68. Moriwaki T, Yasui H, Yamamoto A. 2004. Pharmacokinetic analysis of ramatroban using a recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference in Sprague-Dawley and Eisai hyperbilirubinemic rats. Pharm Res 21:1055-1064.
69. Zhao L. 2009. New developments in using stochastic recipe for multi-compartment model: Inter-compartment traveling route, residence time, and exponential convolution expansion. Math Biosci Eng 6:663-682.
70. Zhao L, Li N, Yang H. 2011. A new stochastic approach to multi-compartment pharmacokinetic models: Probability of traveling route and distribution of residence time in linear and nonlinear systems. J Pharmacokinet Pharmacodyn 38:83-104.
71. Zhao L, Ji P, Li Z, Roy P, Sahajwalla C. in press. The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharm.
72. Gobburu JV, Lesko LJ. 2009. Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol 49:291-301.
73. Schwarz P, Jorgensen NR, Mosekilde L, Vestergaard P. 2012. Effects of increasing age, dosage, and duration of PTH treatment on BMD increase-A meta-analysis. Calcif Tissue Int 90:165-173.
74. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, Demicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Jr., Ridker PM, Kastelein JJ. 2012. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis. JAMA 307:1302-1309.
75. Mandema JW, Boyd RA, DiCarlo LA. 2011. Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: A dose-response meta-analysis. Clin Pharmacol Ther 90:820-827.
76. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R. 2007. Model-based drug development. Clin Pharmacol Ther 82:21-32.
77. Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. 2011. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther 90:828-835.
78. Nixon RM, Bansback N, Brennan A. 2007. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 26:1237-1254.
79. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P. 2009. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: A Cochrane overview. CMAJ 181:787-796.
80. Simeoni M, Magni P, Cammia C, De NG, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M. 2004. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094-1101.
81. US Food and Drug Administration. 2009. Guidance for industry: End-of-phase 2A meetings. Rockville, Maryland: US FDA.